Is Arcellx, Inc. overvalued or undervalued?

As of 8 May 2023, the valuation grade for Arcellx, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 9.00, a negative EV to EBIT of -16.87, and a troubling ROE of -38.96%. In comparison to its peers, Arcellx's EV to EBITDA of -17.41 is less favorable than Arrowhead Pharmaceuticals, which stands at -40.56, but significantly worse than Alvotech's 39.96.
Despite the overvaluation, Arcellx has shown strong short-term performance with a 1-week return of 2.96% compared to the S&P 500's 1.05%, and a 1-month return of 11.36% against 2.33% for the index. However, its year-to-date return of 4.29% lags behind the S&P 500's 12.22%, and its 1-year return of -0.71% is notably underwhelming compared to the S&P's 17.14%. Overall, the company's financial metrics and performance suggest it is overvalued in the current market context.